# Narration and storyboard draft: CCSVI and Liberation Therapy for Multiple Sclerosis

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Liberation therapy proposed that blocked extracranial veins drive multiple sclerosis and that balloon dilation would improve disability. Early uncontrolled reports showed pressure changes and striking improvements in some patients. Blinded studies changed the picture: the Canadian trial found similar transient symptom improvement after sham and venoplasty, while clinical outcomes did not separate. Brave Dreams also found no functional benefit, but only about half of treated participants achieved restored flow. Its expanded analysis later found a positive MRI signal, especially in a post hoc anatomical subgroup. That is a real research lead from the same trial, not independent proof of disability benefit. Diagnostic studies also show narrowing in healthy people and siblings, although some carefully trained ultrasound studies remain positive. Safety is a separate question: thrombosis and device injuries can be caused by treatment, while later systemic events are not automatically attributable. Our Beta rating concerns clinical benefit. The unresolved test requires stable diagnostic criteria, sustained target correction, adequate blinded clinical power and prospective anatomical validation.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.